Psoriasis in Patients With Active Lung Cancer: Is Apremilast a Safe Option?
| Autor: | Athanassios Fassas, Aimilios Lallas, Alexia Koukouthaki, Zoe Apalla, Eftychios Psarakis, Maria Smaragdi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
apremilast Dermatology Malignancy 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Informed consent Psoriasis Genetics medicine In patient Lung cancer Molecular Biology adenocarcinoma treatment business.industry psoriasis Articles medicine.disease Oncology 030220 oncology & carcinogenesis Concomitant RL1-803 Adenocarcinoma Apremilast business phosphodiesterase inhibitor medicine.drug |
| Zdroj: | Dermatology Practical & Conceptual, Vol 9, Iss 4 (2019) |
| Popis: | Concomitant cancers in psoriasis patients often pose significant limitations in treatment decision. In contrast to the majority of the available systemic antipsoriatic drugs, apremilast is not contraindicated in case of previous or concomitant malignancy [1]. We report a patient with psoriasis and lung adenocarcinoma who completely responded to apremilast. The patient provided written informed consent for the data reported in the current manuscript. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|